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BACKGROUND: To investigate the prognostic value of quality of life (QOL) relative to tumour marker carbohydrate antigen (CA) 19-9,
and the role of CA 19-9 in estimating palliation in patients with advanced pancreatic cancer receiving chemotherapy.
METHODS: CA 19-9 serum concentration was measured at baseline and every 3 weeks in a phase III trial (SAKK 44/00–CECOG/
PAN.1.3.001). Patients scored QOL indicators at baseline, and before each administration of chemotherapy (weekly or bi-weekly) for
24 weeks or until progression. Prognostic factors were investigated by Cox models, QOL during chemotherapy by mixed-effect
models.
RESULTS:Patient-rated pain (Po0.02) and tiredness (Po0.03) were independent predictors for survival, although less prognostic than
CA 19-9 (Po0.001). Baseline CA 19-9 did not predict QOL during chemotherapy, except for a marginal effect on pain (Po0.05).
Mean changes in physical domains across the whole observation period were marginally correlated with the maximum CA 19-9
decrease. Patients in a better health status reported the most improvement in QOL within 20 days before maximum CA 19-9
decrease. They indicated substantially less pain and better physical well-being, already, early on during chemotherapy with a maximum
CA 19-9 decrease of X50% vs o50%.
CONCLUSION: In advanced pancreatic cancer, pain and tiredness are independent prognostic factors for survival, although less
prognostic than CA 19-9. Quality of life improves before best CA 19-9 response but the maximum CA 19-9 decrease has no impact
on subsequent QOL. To estimate palliation by chemotherapy, patient’s perception needs to be taken into account.
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Given the poor prognosis of advanced pancreatic cancer and the
symptom burden, symptom palliation and balancing the trade-offs
between quality of life (QOL) and survival are of paramount
importance in these patients. This is particularly the case when
discussing palliative chemotherapy. Quality of life as perceived by
the patient is not only an important treatment outcome but also a
prognostic factor (Gotay et al, 2008; Montazeri, 2009; Quinten
et al, 2009).
Prognostic factors are especially valuable in this situation. Pre-
treatment concentration of the tumour marker carbo-
hydrate antigen (CA) 19-9 is a strong independent prognostic
factor for survival in advanced pancreatic cancer (Micke et al, 2003;
Maisey et al, 2005; Hess et al, 2008). Quality of life also predicts
survival in these patients (Gupta et al,2 0 0 6 ;R o b i n s o net al, 2008).
The contribution of QOL relative to CA 19-9, that is, its clinical
significance as an independent prognostic factor, is not known.
An early decrease in CA 19-9 concentration during chemo-
therapy (i.e., a CA 19-9 response) might not only serve as
prognostic marker but also as an early marker of tumour response.
This would discriminate patients likely to benefit from continued
treatment from those who would not. However, in our recent
phase III trial (Herrmann et al, 2007) a decrease in CA 19-9
concentration during chemotherapy was not significantly
associated with lengthened survival compared with those
patients who did not have a corresponding decrease (Hess et al,
2008).
Whether a decrease in CA 19-9 concentration is associated with
palliation as perceived by the patient is not known. Given that
palliation and thus QOL is a primary treatment goal in these
patients, the question arises whether the CA19-9 response, at any
time for an individual patient, may serve as decision aid for
continuing, switching, or stopping chemotherapy.
We investigated the prognostic value of QOL relative to CA 19-9,
and the role of CA 19-9 in estimating palliation in patients
with advanced pancreatic cancer receiving chemotherapy within
a randomised controlled clinical trial (Herrmann et al, 2007;
Bernhard et al, 2008).
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sPATIENTS AND METHODS
The trial
All patients, with histologically proven, locally advanced, or
metastatic adenocarcinoma of the pancreas, treated in the
international phase III trial SAKK 44/00–CECOG/PAN.1.3.001
(Herrmann et al, 2007) with an elevated baseline tumour marker
CA 19-9 were included in this study. Patients had a Karnofsky
Performance Status (KPS) 460, were naive to chemotherapy for
advanced disease, and had not received any adjuvant radio- or
radiochemotherapy 12 months before inclusion. Patients were
stratified by KPS (90–100 vs 60–80), disease extent (locally
advanced v metastatic), presence or absence of pain, and enrolling
centre and then randomly assigned to GemCap (oral capecitabine
650mgm
 2 twice daily on days 1–14 plus gemcitabine
1000mgm
 2 30-min infusion on days 1 and 8 every 3 weeks)
vs Gem (gemcitabine 1000mgm
 2 30-min infusion weekly for
7 weeks, followed by a 1-week break, and then weekly for 3 weeks
every 4 weeks). Treatment was continued until disease progression
or for a maximum of 24 weeks, except in the case of unacceptable
toxicity. Treatment could be resumed later at the discretion of the
investigator. Treatment decisions were based on clinical and
radiographic grounds, not on CA 19-9 values. Informed consent
was obtained from all patients and ethical committee approval was
given by all participating centres. Trial protocol and conduct are
described elsewhere (Herrmann et al, 2007).
CA 19-9 and tumour response assessment
Carbohydrate antigen 19-9 measurements were performed at
baseline (within 3 days of treatment start) and every 3 weeks
thereafter. The upper limit of laboratory normal (ULN) range was
18–37Uml
 1, depending on the methods used by the different
laboratories involved (La’ulu and Roberts, 2007). Baseline and
follow-up measurements for any given patient were carried out at
the same laboratory and by use of the same testing method.
Patients with a CA 19-9 value 41.0 ULN were included for
baseline analyses (Hess et al, 2008). For the assessment of CA 19-9
response, only patients with baseline values 41.5 ULN and at
least one follow-up value on or after day 42 were included (Hess
et al, 2008). The CA 19-9 best response was defined as the lowest
concentration measured at any time for each individual patient
compared with the baseline value. A CT scan was performed at
baseline, every 6 weeks during chemotherapy and every 9 weeks
during follow-up. Tumour response (i.e., best response during
treatment or follow-up) was assessed according to the Response
Evaluation Criteria In Solid Tumors (Therasse et al, 2000).
QOL assessment
Quality of life was a secondary end point (Bernhard et al, 2008).
Patients were asked to complete a QOL form at baseline and
weekly for the first 7 weeks, and subsequently before each
administration of Gem for 24 weeks from random assignment.
The forms were completed at the hospital and, with the exception
of the baseline, before diagnostic procedures.
For this analysis, we used the following global linear-analogue
self-assessment (LASA) indicators sensitive to the wide spectrum
of reactions seen in patients on chemotherapy: Physical well-being
(Butow et al, 1991), mood (Butow et al, 1991; Hurny et al, 1996),
coping effort (Butow et al, 1991; Hurny et al, 1993), and functional
performance (Bernhard et al, 1999). The indicators for physical
well-being, mood, coping effort, and functional performance were
sensitive to tumour response in metastatic colorectal cancer
(Borner et al, 2005). The issue of high psychological distress in
pancreatic cancer (Zabora et al, 2001) was covered by the mood
and coping indicators, which are sensitive to mood disorders and
psychosocial dysfunction (Bernhard et al, 2001). Specific LASA
indicators were used for pain (Fishman et al, 1987) and tiredness
(Bernhard et al, 1999). The restriction to a few key indicators
instead of a standard assessment was based on feasibility
considerations for the intensive longitudinal assessment schedule
(Bernhard et al, 2008).
Statistical analysis
Quality of life forms filled in 43 days before or after day 1 of a
cycle were excluded. We report means of untransformed data
(scale range: 0–100; higher scores: better condition). A mean
change of X8 points from baseline was defined as clinically
meaningful (Sloan and Dueck, 2004).
Associations among the stratification factors, baseline CA 19-9
and QOL scores (grouped by medians), and tumour response
(Therasse et al, 2000) were investigated by w
2-tests, associations
among the continuous QOL scores by Spearman correlations.
We used RX0.7 as criterion for multi-collinearity (Van Steen et al,
2002).
A Cox model for overall survival was calculated with stratifica-
tion factors, treatment arm, and baseline CA 19-9 as predictors.
Then the QOL indicators were added individually to the model,
first with continuous and second with grouped scores (cut-off
points: 33 and 67% quantile of total sample, intermediate group as
reference). The findings of the grouped scores were more
consistent due to nonlinear effects, and are presented here. A
second Cox model was calculated for all QOL indicators without
clinical factors and a third model with clinical factors and QOL
indicators.
Associations between QOL changes and maximum CA 19-9
decrease (both to baseline) were explored by Spearman correla-
tions. The prognostic value of CA 19-9 baseline concentration and
CA 19-9 maximal decrease for QOL during chemotherapy was
investigated by a linear mixed-effects model for each indicator
taking into account time effects on QOL, split by monthly
treatment duration (Bernhard et al, 2008).
The time before and after best CA 19-9 response was divided
into four periods. They were defined as the smallest intervals
coinciding with weekly QOL assessments and yielding robust
associations. Mean QOL changes by maximum CA 19-9 decrease of
o50 vs X50% were investigated by a linear mixed-effects model
over these periods for each indicator. Baseline QOL was used as a
covariate and the number of forms included in a patient’s period
mean as a weight variable.
RESULTS
Sample description and patient characteristics
Out of 319 randomised patients, four did not receive trial
treatment and four had no visit forms. Of the remaining 311
patients, 96% had a baseline QOL form. Of all expected QOL
forms under treatment, we received 86% (N¼3033/3536). Of
those, 95% were filled in at day 1 or within 3 days before a
chemotherapy cycle. Participants and non-participants at the last
scheduled QOL assessment (week 23) were similar regarding age,
sex, disease status, KPS, and pain requiring medication at random
assignment (data not shown). A majority of patients had
metastatic disease and pain requiring analgesic medication
(Table 1).
According to our criteria for CA 19-9 evaluation, 247 patients
were assessable at baseline. There were no apparent differences
between these patients and the total sample (data not shown), and
between those with normal and increased (median¼59 ULN)
CA 19-9 baseline concentration (Table 1). Of the 247 patients with
increased concentration, 175 had at least one follow-up assessment
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response.
Associations among patient characteristics, CA 19-9, and
QOL at baseline
The only tendency for an association between the baseline
characteristics and normal vs increased CA 19-9 concentration was
the proportion of patients requiring analgesic medication according
to the treating physician (Table 1), with a higher proportion (70 vs
58%) in the group with increased concentration (P¼0.12), but no
difference in average analgesic consumption at this time.
The baseline QOL scores are shown by CA 19-9 concentration in
Table 2. Those for coping effort, tiredness, and mood were
particularly impaired. There was no substantial association
between QOL and CA 19-9 or extent of disease at baseline.
Patients with lower KPS had significantly worse scores in all QOL
indicators (data not shown). The correlations among the QOL
indicators ranged between R¼0.32 and 0.64. There was no
indication for harmful multi-collinearity.
Prognostic value of baseline QOL
Baseline QOL was not associated with tumour response (CR/PR:
N¼27; SD: N¼173; PD: N¼53). Similarly, there was no
association between baseline CA 19-9 and tumour response, as
reported previously (Hess et al, 2008). There was no substantial
correlation between baseline QOL and best CA 19-9 response (i.e.,
absolute value) or maximum (i.e., relative) decrease of CA 19-9.
In the total sample (N¼319), the median time to progression
(TTP) was 4.3 and 3.9 months in patients randomly assigned to
GemCap or Gem, respectively (Herrmann et al, 2007); that is, the
majority of patients failed during our observation period of 6
months. In a Cox model with stratification factors, treatment arm
and baseline CA 19-9 41 ULN (N¼247; TTP GemCap and Gem:
4.4 and 3.9 months), the strongest effect was present for CA 19-9,
followed by physician-rated KPS and pain requiring analgesic
medication, as shown in Table 3. After adding the QOL indicators
separately, tiredness (good vs intermediate) was additionally
prognostic, with less tiredness resulting in a better survival (HR:
0.68, 95% CI: 0.48-0.96, Po0.05). Similarly, patients who reported
less pain (good vs intermediate) had a better survival (HR: 0.69,
95% CI: 0.48–0.98, Po0.05). It is important to note that these
effects were not linear but discriminated patients with low
symptom burden from the others. The remaining indicators were
not associated with survival. Pain and tiredness (borderline effect)
were also the only prognostic indicators in the model without
clinical factors (Table 3).
Finally, a Cox model was calculated including both the clinical
factors and QOL indicators (Table 3). Patient-rated pain intensity
was more prognostic than pain requiring analgesic medication
according to the treating physician. In contrast, patient-rated
functional performance remained unprognostic after exclusion of
KPS. Survival according to tiredness and pain intensity is shown in
Figure 1. A univariate analysis of all available patients (including
CA 19-9 p1 ULN) showed similar findings.
Associations between CA 19-9 and QOL during
chemotherapy
Mean changes in physical QOL domains across the whole
observation period were marginally correlated with the maximum
CA 19-9 decrease, ranging from R¼0.15 (Po0.05) for functional
performance to R¼0.28 (Po0.001) for physical well-being. To
investigate the role of CA 19-9 in estimating palliation, we first
explored the prognostic value of CA 19-9 baseline concentration
and of maximal decrease for QOL during chemotherapy by mixed-
effects models using all available data until failure (N¼231). The
only, but not relevant, difference by baseline CA 19-9 was present
in pain: Patients with baseline CA 19-9 below the median indicated
marginally less pain on treatment (average score: 8.5 vs 8.3
Po0.05). The maximum CA 19-9 decrease had no impact on any of
the QOL indicators after best response; that is, the scores were
similar to those before best response. There was no significant
interaction between CA 19-9 baseline scores and maximum
decrease (P¼0.1), time effects on QOL, or time on study
treatment.
Second, we explored the changes in QOL from baseline
according to their timing relative to the best CA 19-9 response
in a subsample. Four periods were defined: X21 days (period 1)
or o21 days (2) before best CA 19-9 response, and o21 days (3)
or X21 days (4) after best response. Eighty-five patients
with baseline CA 19-9 X1.5 ULN, CA 19-9 measurements
after day 40, and QOL measurements in all four periods were
available (TTP GemCap and Gem: 7.1 and 5.8 months). For a
conservative estimate of QOL, all measurements were averaged
within each period for each patient and indicator. In this relatively
healthy subsample, there was an improvement in all periods
and indicators (Figure 2). The largest improvement was within
20 days before the best response of CA 19-9, with mean changes
varying between 7.6 for mood and 11.7 for coping effort. After the
best CA 19-9 response, QOL tended to decline but remained above
baseline.
Table 2 Quality of life scores of the total sample by tumour marker
concentration at baseline
a
Increased tumour
marker concentration
(N¼236–238)
b
Normal tumour
marker concentration
(N¼45–46)
c
Median Range Median Range
Pain intensity 83 6–100 88 5–100
Tiredness 62 2–100 70 2–100
Physical well-being 71 1–100 72 4–100
Functional performance 70 1–100 62 1–100
Mood 63 0–100 59 3–100
Coping effort 57 0–100 60 4–100
Abbreviations: CA¼carbohydrate antigen; ULN¼upper limit of laboratory normal.
aHigher scores indicate a better condition (e.g., less coping effort).
bIncreased CA
19-9: 4 1 ULN; median (range): 59 (1–90032).
cNormal CA 19-9: p1 ULN.
Table 1 Characteristics and quality of life scores of the total sample by
tumour marker concentration at baseline
Increased tumour
marker
concentration
(N¼247)
a
Normal tumour
marker
concentration
(N¼48)
b
Median age/range (years) 63/26–83 61/36–73
Male/female (%) 47/53 46/54
Extent of disease: locally
advanced/metastatic (%)
22/78 17/83
Karnofsky performance status
90–100/60–80 (%) 54/46 50/50
Pain requiring medication (%)
c 70 58
Average baseline analgesic
consumption (morphine-
equivalent mg) over 4 days
(median/range)
0/0–104 0/0–101
Abbreviations: CA¼carbohydrate antigen; ULN¼upper limit of laboratory normal.
aIncreased CA 19-9: 41 ULN; median (range): 59 (1–90032).
bNormal CA 19-9:
p1 ULN.
cAccording to the treating physician.
CA 19-9 tumour marker and quality of life
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change of each indicator was grouped for each period as ‘better’,
‘stable’, or ‘worse’ relative to baseline, according to our pre-defined
criterion (mean change of X8 points from baseline in either
direction). With some variation among the periods and indicators,
more than two-thirds of the patients reported stable or improving
scores regardless of the period. In other words, there was no
indication that a minimally important change in QOL was associated
with the timing relative to the best CA 19-9 response. It is noteworthy
that all these patients received trial chemotherapy in all four periods.
Table 3 Prognostic value of baseline factors for overall survival in patients with an increased tumour marker concentration
Cox model for
clinical factors
Cox model for
QOL factors
Cox model for clinical
and QOL factors
Factor Hazard ratio 95% CI P Hazard Ratio 95% CI P Hazard ratio 95% CI P
Stratification factor
Pain requiring medication 0.73 0.54–0.98 0.035 —
a
Locally advanced vs metastatic disease 0.81 0.58–1.13 0.222 0.79 0.55–1.11 0.174
Karnofsky performance status of 90–100 vs 60–80 0.73 0.56–0.96 0.025 0.67 0.48–0.94 0.02
Treatment arm GemCap vs Gem 0.91 0.69–1.18 0.467 0.83 0.62–1.10 0.184
Tumour marker CA 19-9 low (p59 ULN)
vs high (459 ULN)
0.48 0.36–0.64 o0.001 0.41 0.30–0.55 o0.001
QOL indicators:
Tiredness
Poor vs intermediate 1.07 0.74–1.54 0.737 1.04 0.72–1.49 0.847
Good vs intermediate 0.7 0.48–1.03 0.07 0.65 0.45–0.96 0.03
Pain
Poor vs intermediate 0.87 0.61–1.23 0.429 0.75 0.52–1.09 0.129
Good vs intermediate 0.65 0.45–0.93 0.019 0.63 0.44–0.92 0.015
Physical well-being
Poor vs intermediate 1.17 0.77–1.77 0.453 1.09 0.72–1.65 0.691
Good vs intermediate 1.16 0.79–1.70 0.452 1.33 0.90–1.96 0.157
Functional performance
Poor vs intermediate 0.8 0.55–1.17 0.246 —
b
Good vs intermediate 0.9 0.60–1.35 0.621
Mood
Poor vs intermediate 1.01 0.68–1.50 0.946 1.07 0.72–1.59 0.741
Good vs intermediate 0.92 0.63–1.33 0.654 0.94 0.64–1.38 0.759
Coping effort
Poor vs intermediate 0.89 0.61–1.29 0.523 0.76 0.51–1.12 0.161
Good vs intermediate 0.96 0.67–1.38 0.836 1.01 0.71–1.43 0.963
Abbreviations: CA¼carbohydrate antigen; CI¼confidence interval; QOL¼quality of life; ULN¼upper limit of laboratory normal.
aPain requiring medication according the
treating physician was replaced by patient-rated pain intensity.
bPatient-rated functional performance was replaced by Karnofsky performance status. Bold values indicate statistical
significance or borderline effect.
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Figure 1 Overall survival by baseline scores of tiredness (cut-off points: 50, 77) and pain (cut-off points: 71, 92). Both indicators have a range from
0 to 100, with higher scores indicating a better condition. P-values are based on log-rank test.
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maximum CA 19-9 decrease in this subsample. Figure 3 shows
individual changes in pain across the four periods split by the cut-
off of o50 vs X50% maximum decrease. Patients with a maximum
CA 19-9 decrease of o50% (N¼14) indicated stable scores or an
improvement at beginning, and a declining tendency over time
(mean change to baseline¼ 1). Those with a decrease of at least
50% (N¼71) showed in average an early improvement in pain,
which remained roughly stable (mean change to baseline¼10;
group difference: Po0.005). Similarly, patients with a maximum
decrease of at least 50% indicated better physical well-being across
all periods, with an overall change in physical well-being of 9 as
compared with 0 (Po0.05).
Within these four periods, changes in pain and physical well-being
were weakly correlated with the maximum CA 19-9 decrease, more
prominent after best CA 19-9 response as compared to before (e.g.,
pain o21 days before: R¼0.27, Po0.05; o21 days after: R¼0.34,
Po0.005). To estimate whether this correlation was depending on the
initial tumour load, patients were grouped according to the median
CA 19-9 concentration at baseline. Only patients with a value below
the median (27 ULN) showed a significant correlation between
maximum CA 19-9 decrease and changes in pain within 20 days
before (R¼0.37, Po0.05). These patients reported better pain scores
at baseline (median: 89.5 vs 67.0; Po0.05).
In summary, baseline CA 19-9 had no relevant prognostic impact
on QOL until treatment failure. There was an association between the
maximum CA 19-9 decrease and pain and physical well-being,
respectively, but the maximum decrease was not prognostic for these
domains: These group differences in pain and physical well-being
were present already before the maximum decrease.
DISCUSSION
We investigated the prognostic value of QOL relative to CA 19-9,
and the role of CA 19-9 in estimating palliation in patients with
advanced pancreatic cancer receiving chemotherapy within a
randomised controlled clinical trial (Herrmann et al, 2007;
Bernhard et al, 2008).
At baseline, less pain and tiredness, that is, less symptom
burden, predicted better survival, as shown for various QOL
domains in other cancer sites (Gotay et al, 2008; Montazeri, 2009;
Quinten et al, 2009). In advanced disease, mainly physical
functioning and symptoms have been prognostic. Pre-treatment
fatigue was a dominant prognostic factor in patients with advanced
head and neck carcinoma treated with radiotherapy (Fang et al,
2004). Similarly, pain and dysphagia were strong prognostic
factors in patients with non-small-cell lung cancer (Efficace et al,
2006). We did not assess further patient-rated symptoms in our
trial. Pain and tiredness showed consistent findings in all models.
Their nonlinear association with survival may be confounded by
individual analgesic treatment before the baseline assessment.
These symptoms may serve as baseline characteristics for patients
with advanced pancreatic cancer treated in clinical trials. Their
relative contribution is, however, smaller than the effect of pre-
treatment concentration of CA 19-9 on survival.
In contrast, baseline CA 19-9 did not predict QOL or time on
study treatment, besides a marginal effect on pain. Neither CA 19-9
nor QOL predicted tumour response to chemotherapy. Survival is
influenced by different factors than response to chemotherapy,
although response impacts on survival. Thus, CA 19-9 and QOL at
baseline provide limited information for estimating palliation by
chemotherapy.
In patients with a better health status, QOL during chemother-
apy differed by the timing relative to the best CA 19-9 response.
Twenty days before the best CA 19-9 response, patients reported
the most improvement from baseline. The subsequent QOL scores,
however, were not affected by the maximum CA 19-9 decrease. The
maximum decrease had an effect on physical domains across the
whole observation period: Those patients with a better CA 19-9
response had better scores already early on chemotherapy. There
was no indication that a minimal important change in QOL was
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Thus, the shift in QOL preceding the best CA 19-9 response and
the maximum decrease of CA 19-9 provide little information on
the net palliation by chemotherapy. The decision of whether to
continue switch or stop chemotherapy cannot be made on the
basis of early CA19-9 kinetics alone. The patient’s experience of
disease and treatment as a whole needs to be taken into account.
In our trial, QOL improved under chemotherapy and deterio-
rated again before treatment failure was documented by the
clinician (Bernhard et al, 2008). The majority of those patients
receiving only few cycles indicated a benefit from chemotherapy
(Bernhard et al, 2008). There were no effects by the randomly
assigned treatment groups (gemcitabine vs gemcitabine plus
capecitabine) on survival, QOL, or clinical benefit (Bernhard
et al, 2008). It remains unclear, whether the palliation as indicated
by patients’ QOL was caused by a very brief antitumour effect by
chemotherapy or by the conditions of the situation itself, for
example, receiving antitumour treatment, supportive care or more
steroids than before. Some associations between maximum CA
19-9 decrease and pain or physical well-being may reflect both the
impact of anti-tumour or analgesic treatment.
Several limitations of this study have to be noted. The predictive
and prognostic value of baseline QOL was specified in the protocol.
However, our findings are based on a secondary analysis of a phase
III trial. Their clinical validity is restricted by potential selection
criteria bias. An observational study would provide more evidence
of the prognostic value of baseline QOL. A comprehensive
standard QOL assessment would have given supplemental
information on symptoms and broader domains of functioning
and well-being, but was not feasible for our intensive assessment
schedule (Bernhard et al, 2008). We hypothesised that the different
time schedules used in previous trials in this population
contributed to the inconsistent findings on the impact of single-
agent gemcitabine on QOL (Bernhard et al, 2008). To minimise the
potential bias associated with early withdrawal from study
treatment and to investigate patients’ underlying trajectories of
palliation, we have chosen a weekly or fortnightly assessment for
QOL over 6 months that revealed consistent time effects (Bernhard
et al, 2008). We selected simple indicators as an alternative to a
comprehensive questionnaire, which is better suited for widely
spaced estimates. There was no indication for multi-collinearity
using these indicators (Van Steen et al, 2002). Finally, this
investigation is based on different subsamples, including patients
in a relatively good health status. Overall, however, the findings of
the different analyses are consistent.
In conclusion, in advanced pancreatic cancer, pain and tiredness
are independent prognostic factors for survival, although they are
less prognostic than CA 19-9. Neither CA 19-9 nor QOL did predict
tumour response. Baseline CA 19-9 does not predict QOL under
chemotherapy. QOL improves before best CA 19-9 response but
the maximum decrease has no impact on subsequent QOL. Best CA
19-9 response alone does not provide sufficient information about
palliation by chemotherapy. Patient’s perception needs to be taken
into account.
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